Current Trials:

June-1, 2020

The SQUID Trial for the Embolization of the Middle Meningeal Artery for Treatment of Chronic Subdural Hematoma (STEM) (STEM)

STEM Study is a pivotal, international, multi-center, prospective, randomized (1:1) controlled trial designed to provide an assessment of the safety and effectiveness of Middle Meningeal Artery (MMA) embolization with SQUID for the management of Chronic Subdural Hematoma (cSDH).



May-14, 2020

BALT RECEIVES IDE APPROVAL FROM THE FDA TO BEGIN THE STEM TRIAL

May 14, 2020 IRVINE, Calif.–(BUSINESS WIRE)–Balt announced today it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin The Squid Trial for…

READ MORE

New launch:

Balt Introducing brand new Device XYZ

  • Device XYZ is especially design for Neurovascular Access.
  • Device XYZ features 1
  • Device XYZ features 2

Balt Launch Device ABC

  • Sample New Launche 2

Events:

Conference XYZ

  • New York, USA September 24 2021-September 27 2021

Sample TDRS 2021

  • Chicago, USA December 2 2021- December 9 2021

News / bulletins:

21 January 2021

FDA approves MAGIC Infusion Catheter

READ MORE


20 February 2020

OPTIMA COIL SYSYTEM seeks approval from FDA Device

READ MORE



20 Mar 2018

BALT USA, LLC ANNOUNCES 510(K) CLEARANCE OF THE OPTIMA™ COIL SYSTEM AND NEW BALT USA HEADQUARTERS

March 20, 2018 IRVINE, CA – Balt USA announces today it has received 510(k) clearance for the Optima™ Coil System and completion of first clinical cases in the United States. …

READ MORE

Recalls:

Recalls Sample 1

  • Balt recalls XYZ device.....Read more

Recalls Sample 2

  • Balt recalls the TMO device again....Read more

Device Notifications:

Sample Device Notification

  • ABC update soon

Sample Articles Notification

  • Prof Dr. XYZ release there article on ABC device.